<?xml version="1.0" encoding="UTF-8" ?><!-- Generated on Thu, 21 May 2026 22:06:56 -0400--><rss version="2.0">
    <channel>
        <title>Castle Biosciences, Inc. (CSTL) In The Media</title>
        <link>https://ir.castlebiosciences.com/news-events/in-the-media/rss</link>
        <description></description>
        <language>en-us</language>
                                            <image>
                <url>https://d1io3yog0oux5.cloudfront.net/castlebiosciences/files/theme/images/logo-sm.png</url>
                <title>Castle Biosciences, Inc. Logo</title>
                <link></link>
            </image>
                <generator>Equisolve Investor Relations Suite</generator>
        
                            <item>
                <title><![CDATA[Targeted Oncology: Prospective Data Support i31-SLNB Test to Guide Biopsy Use in Melanoma]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.targetedonc.com/view/prospective-data-support-i31-slnb-test-to-guide-biopsy-use-in-melanoma</link>
                <pubDate>Mon, 16 Mar 26 00:00:00 -0400</pubDate>
                <guid>https://www.targetedonc.com/view/prospective-data-support-i31-slnb-test-to-guide-biopsy-use-in-melanoma</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Dermatology Times: Determining Biologic or JAKi Efficacy for Patients With Moderate to Severe AD Through GEP Testing]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.dermatologytimes.com/view/determining-biologic-or-jaki-efficacy-for-patients-with-moderate-to-severe-ad-through-gep-testing</link>
                <pubDate>Fri, 13 Mar 26 00:00:00 -0400</pubDate>
                <guid>https://www.dermatologytimes.com/view/determining-biologic-or-jaki-efficacy-for-patients-with-moderate-to-severe-ad-through-gep-testing</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[The CEO Magazine: Meet the Judges for the 2026 Executive of the Year Awards – United States]]></title>
                <description><![CDATA[]]></description>
                <link>https://amp.theceomagazine.com/events/meet-the-judges-united-states/</link>
                <pubDate>Thu, 12 Mar 26 00:00:00 -0400</pubDate>
                <guid>https://amp.theceomagazine.com/events/meet-the-judges-united-states/</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[CancerNetwork: DecisionDx-Melanoma Test Predicts Nodal Positivity in Cutaneous Melanoma]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.cancernetwork.com/view/decisiondx-melanoma-test-predicts-nodal-positivity-in-cutaneous-melanoma</link>
                <pubDate>Wed, 11 Mar 26 00:00:00 -0400</pubDate>
                <guid>https://www.cancernetwork.com/view/decisiondx-melanoma-test-predicts-nodal-positivity-in-cutaneous-melanoma</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[American Journal of Managed Care (AJMC): Gene Expression Profile Helps Predict Atopic Dermatitis Therapy Response]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.ajmc.com/view/gene-expression-profile-helps-predict-atopic-dermatitis-therapy-response</link>
                <pubDate>Wed, 11 Mar 26 00:00:00 -0400</pubDate>
                <guid>https://www.ajmc.com/view/gene-expression-profile-helps-predict-atopic-dermatitis-therapy-response</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Dermatology Times: AdvanceAD-Tx Gene Expression Profile Test May Help Guide Systemic Therapy Selection in Atopic Dermatitis]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.dermatologytimes.com/view/advancead-tx-gene-expression-profile-test-may-help-guide-systemic-therapy-selection-in-atopic-dermatitis</link>
                <pubDate>Wed, 11 Mar 26 00:00:00 -0400</pubDate>
                <guid>https://www.dermatologytimes.com/view/advancead-tx-gene-expression-profile-test-may-help-guide-systemic-therapy-selection-in-atopic-dermatitis</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Pulse 2.0: Castle Biosciences: Interview With Founder, CEO, And President Derek Maetzold About The Molecular Diagnostics Company]]></title>
                <description><![CDATA[]]></description>
                <link>https://pulse2.com/castle-biosciences-profile-derek-maetzold-interview/</link>
                <pubDate>Thu, 05 Mar 26 00:00:00 -0500</pubDate>
                <guid>https://pulse2.com/castle-biosciences-profile-derek-maetzold-interview/</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[The Pathologist: Gene Test Guides Eczema Care]]></title>
                <description><![CDATA[]]></description>
                <link>https://thepathologist.com/issues/2026/articles/march/gene-test-guides-eczema-care/</link>
                <pubDate>Mon, 02 Mar 26 00:00:00 -0500</pubDate>
                <guid>https://thepathologist.com/issues/2026/articles/march/gene-test-guides-eczema-care/</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[JDNPPA: Castle’s AdvanceAD-Tx Identifies AD Patients Who Are More Likely to Respond to JAK Inhibitors]]></title>
                <description><![CDATA[]]></description>
                <link>https://jdnppa.com/castles-advancead-tx-identifies-ad-patients-who-are-more-likely-to-respond-to-jak-inhibitors/</link>
                <pubDate>Wed, 25 Feb 26 00:00:00 -0500</pubDate>
                <guid>https://jdnppa.com/castles-advancead-tx-identifies-ad-patients-who-are-more-likely-to-respond-to-jak-inhibitors/</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[The Dermatology Digest: Personalized Medicine in Action: Castle’s AdvanceAD-Tx Identifies AD Patients Who Are More Likely to Respond to JAK Inhibitors]]></title>
                <description><![CDATA[]]></description>
                <link>https://thedermdigest.com/personalized-medicine-in-action-castles-advancead-tx-identifies-ad-patients-who-are-more-likely-to-respond-to-jak-inhibitors/</link>
                <pubDate>Fri, 20 Feb 26 00:00:00 -0500</pubDate>
                <guid>https://thedermdigest.com/personalized-medicine-in-action-castles-advancead-tx-identifies-ad-patients-who-are-more-likely-to-respond-to-jak-inhibitors/</guid>
                                                                            </item>
            </channel>
</rss>